ther evaluation. Informed consent was obtained from the patient before bone marrow study and genetic testing.
Her complete blood count (CBC) revealed a white blood cell count of 1.7 × 10 9 /L (segmented neutrophils, 50%; band form neutrophils, 2%; lymphocytes, 44%; monocytes, 3%; and eosinophils, 1%), an Hb level of 62 g/L, and a platelet count of 272 × 10 9 /L. The initial mean corpuscular volume was decreased to 65.8 fL. A peripheral blood smear showed poikilocytosis with teardrop-shaped red blood cells ( Fig. 1A ). An abdominal computed tomography showed mild hepatosplenomegaly, and serum lactate dehydrogenase level was elevated to 5.3 μkat/L (reference range: 2.3-4.5 μkat/L).
The initial bone marrow biopsy done in May 2017 revealed inadequate aspirate due to dry tap. The core biopsy showed normal cellularity (50%) with megakaryocytic hyperplasia and atypia. The megakaryocytes were increased in number and formed small to large clusters with anisocytosis. Osteosclerosis was not significant ( Fig. 1B ). Grade MF-2 bone marrow fibrosis was identified by reticulin stain (Fig. 1C ), and grade 1 collagen deposition was detected by Masson's trichrome stain. Neither necrosis nor granuloma was observed in the bone marrow. Chromosome testing showed solitary trp(1)(q21q32) in all 20 metaphase cells (Fig. 1D ). JAK2-V617F, CALR, and MPL mutations were all tested negative. In addition, no other pathogenic variant was identified in the AML gene panel testing including 45 genes such as ASXL1, EZH2, TET2, IDH1, IDH2, SRSF2, and SF3B1. Acid-fast bacilli staining and tuberculosis culture of bone marrow samples were negative. The patient was diagnosed as having PMF based on the 2016 revision of the WHO classification [4] .
Following anti-tuberculosis therapy with oral isoniazid, rifampicin, ethambutol, and pyridoxine, the miliary tuberculosis im-proved. However, the bicytopenia persisted for eight months after treatment; the follow-up (21 months after the first evaluation) bone marrow study and chromosome test results were the same as the previous ones.
Of the previous two cases of 1q triplication in MPN patients, one was reported during the follow-up of chronic myeloid leukemia (CML), and the other case was detected as the sole cytogenetic abnormality in a PMF patient with a BCR/ABL1 negative state following CML treatment [2] ; in this case, unlike the previous reports, 1q triplication was reported in a PMF patient without evidence of other hematologic malignancies (Table 1) .
Approximately 12% of patients with PMF have been reported as triple-negative for JAK2-V617F, CALR, and MPL mutations [4] . In these cases, searching for frequent accompanying mutations is helpful in determining the clonality of the disease [4, 5] . In our case, no mutation was found in the AML gene panel test; thus, the only evidence of clonality was 1q triplication. As previously established, 1q duplication is one of the most common abnormalities in PMF [5] [6] [7] . In addition, 33% of the reported 1q triplication cases (11/33) and 60% of the solitary 1q triplication cases (3/5), including the present study, share a triplicated region on 1q21 to 1q32 [1] [2] [3] . Thus, there might be a correlation between the 1q21 to 1q32 region and the pathogenesis of hematologic malignancies.
In conclusion, this is the first case of sole1q triplication in a patient with PMF without other hematologic malignancies. Further study is needed to confirm the pathogenesis of 1q triplication in the myeloproliferative process.
